Value-Based Care in Myeloma

Combination Therapies Dominate NCCN Guidelines for Multiple Myeloma

Wayne Kuznar

October 2017 - Multiple Myeloma

Orlando, FL—The ideal treatment in 2017 for patients with newly diagnosed multiple myeloma is a combination of bor­tezomib (Velcade), lenalidomide (Revlimid), and dexamethasone. Bortezomib-based maintenance therapy is particularly relevant in patients with high-risk disease and residual disease, and in the relapsed setting, triplet therapy is preferred over doublet therapy. [ Read More ]

Daratumumab Added to Carfilzomib, Lenalidomide, and Dexamethasone: Safe and Tolerable in Patients with Newly Diagnosed Multiple Myeloma

Chase Doyle

August 2017, Vol 8, No 4 | Payers’ Perspectives In Oncology: ASCO 2017 Highlights - Multiple Myeloma

Chicago, IL—In patients with newly diagnosed multiple myeloma, the addition of daratumumab to carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (ie, the KRd regimen) is showing promise as a frontline treatment regimen. According to the results of an open-label, phase 1b study presented at ASCO 2017, induction therapy with the KRd regimen was well-tolerated, and the overall safety profile was consistent with previous reports for KRd, with no additional toxicity observed with the addition of daratumumab. Moreover, the study investigators reported that the regimen was very effective, with 100% overall response rate observed. [ Read More ]

Additional Interventions Do Not Boost Outcomes Over Single Transplant in Patients with Multiple Myeloma

Phoebe Starr

June 2017 - Multiple Myeloma

Additional interventions after upfront autologous hematopoietic stem-cell transplantation (HSCT) in patients with multiple myeloma failed to provide further improvement in progression-free survival (PFS) or overall survival (OS) compared with single autologous HSCT, according to results from the multicenter STaMINA clinical trial presented at the 2016 American Society of Hematology meeting. [ Read More ]

HIV Drug Shows Promise in Refractory Multiple Myeloma

Charles Bankhead

February 2017, Vol 8, No 1 - Multiple Myeloma

San Diego, CA—Nelfinavir (Viracept), a drug used for HIV, led to a surprisingly high response rate when added to bor­tezomib (Velcade) in patients with proteasome inhibitor–refractory multiple myeloma, according to a phase 2 study reported by Christoph Driessen, MD, myeloma specialist, Kantonsspital St. Gallen, Switzerland, at the 2016 American Society of Hematology meeting. [ Read More ]

American Society of Hematology 2016: Multiple Myeloma Highlights

February 2017, Vol 8, No 1 - Multiple Myeloma

  • Adding Daratumumab to Lenalidomide and Dexamethasone in Previously Treated Patients with Relapsed or Refractory Multiple Myeloma Improves Outcomes
  • Real-World Evidence Regarding Newer Treatment Options, Overall Survival, and Healthcare Costs in Patients with Multiple Myeloma
  • Long-Term Analysis of the CASTOR Trial: Adding Daratumumab to Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
  • The Use of Early Response Can Guide Treatment Selection in Patients with Newly Diagnosed Multiple Myeloma
  • Using Montelukast to Reduce Infusion Reactions in Patients with Relapsed or Refractory Multiple Myeloma
[ Read More ]